India's Keytruda Market to See Continued Growth, Driven by Expanding Cancer Indications and Immunotherapy Adoption
The India Keytruda Market, centered around Merck & Co.'s pioneering immunotherapy drug pembrolizumab, is progressively establishing its footprint in the country's oncology landscape. As India grapples with a rising cancer burden and increasing awareness of advanced treatment options, Keytruda, known for its broad efficacy across numerous tumor types, is playing an increasingly vital role. While specific, granular market size data for Keytruda only in India is not publicly disaggregated, the global Keytruda market was valued at US$ 27.09 billion in 2024 and is projected to reach nearly US$ 54.78 billion by 2032, growing at a CAGR of 9.20%. India, as part of the rapidly growing Asia-Pacific cancer immunotherapy market (forecast to register the fastest 18.22% CAGR through 2030), is expected to be a key contributor to this growth, with significant potential for immunotherapy adoption.
India's oncology market is witnessing a profound shift towards targeted therapies and immunotherapies, and Keytruda is at the forefront of this transformation.
Key Market Drivers and Trends:
Rising Cancer Incidence: India faces an escalating burden of cancer, with an estimated 1.5 million new cases diagnosed annually. Common cancers such as lung, breast, head and neck, and gastrointestinal cancers, for which Keytruda has approved indications globally, are prevalent. This large and growing patient pool creates a substantial demand for effective cancer therapies, including advanced immunotherapies.
Expanding Indications and Efficacy: Keytruda's approval for a wide range of cancer types globally, including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma, and various others, positions it as a versatile treatment option. Its demonstrated clinical efficacy in improving progression-free survival (PFS) and overall survival (OS) compared to traditional chemotherapy in various settings is a major driver for its adoption by oncologists. While Lung Cancer dominated the global Keytruda market in 2024, Breast Cancer is projected to be the fastest-growing segment, highlighting its expanding utility.
Growing Oncologist Awareness and Adoption: As Indian oncologists gain more experience with immunotherapies through clinical trials and real-world evidence, there's increasing confidence in prescribing drugs like Keytruda. Continuous medical education and scientific conferences contribute to wider adoption among the medical fraternity.
Emergence of Personalized Medicine: India is gradually moving towards personalized medicine in oncology. The availability and increasing utilization of biomarker testing, such as PD-L1 expression, help identify patients who are most likely to benefit from Keytruda, thereby optimizing treatment outcomes and resource allocation.
Improving Healthcare Infrastructure (Tier I & II Cities): While access remains a challenge in rural areas, metropolitan and Tier I cities in India are witnessing significant upgrades in healthcare infrastructure, including the establishment of well-equipped cancer centers capable of administering complex immunotherapies and managing their side effects. These centers also have the necessary diagnostic capabilities for biomarker testing.
Government Initiatives and Health Insurance Schemes: While high drug costs remain a significant barrier, government schemes like the Health Minister's Cancer Patient Fund (HMCPF) under the Rashtriya Arogya Nidhi (RAN) provide financial assistance to eligible cancer patients, though often limited to specific treatments and regional cancer centers. The increasing penetration of private health insurance, especially among the middle and upper-income groups, also improves affordability and access to high-cost innovative therapies like Keytruda.
Development of Subcutaneous Formulations: Merck's global efforts to develop a subcutaneous formulation of Keytruda could significantly impact the Indian market. A subcutaneous option would reduce infusion time, enhance patient convenience, potentially lower administration costs (by reducing clinic visits or chair time), and improve accessibility, particularly important in a country with vast distances and varying levels of healthcare facilities.
Despite challenges such as the high cost of the drug, which limits affordability for a large segment of the population, and the need for stronger reimbursement mechanisms, the India Keytruda Market is poised for continued growth. As cancer awareness increases, diagnostic capabilities improve, and healthcare infrastructure expands, Keytruda will remain a crucial component of India's evolving cancer treatment landscape, offering new hope to patients.
About Market Research Future (MRFR)
Market Research Future (MRFR) is a global market research firm that provides comprehensive insights into market trends, drivers, challenges, and opportunities. We offer a broad range of market intelligence reports and consulting services to help businesses and enterprises in various industries make informed decisions.
Media Contact:
Market Research Future (MRFR)
Phone: +1-646-845-9312
Email: contact@marketresearchfuture.com
Website: marketresearchfuture